XML 75 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Operations (Unaudited) (USD $)
 12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Revenues:      
License fee and milestone revenue $ 82,536 $ 156,397 $ 213,916
License fee and milestone revenue from affiliated entity 425,000 411,459 313,306
Revenue under collaborative research and development arrangements with affiliated entity 152,467 0 0
Grants and miscellaneous revenue 3,458,649 9,227,401 5,549,583
Miscellaneous revenue from affiliated entity 0 0 67,900
Total revenues 4,118,652 9,795,257 6,144,705
Operating expenses:      
Research and development 17,984,825 20,032,001 13,256,606
General and administrative 10,778,359 11,988,796 12,108,261
Gain on sale of intangible assets (1,151,000) (587,000) 0
Total operating expenses 27,612,184 31,433,797 25,364,867
Loss from operations (23,493,532) (21,638,540) (19,220,162)
Other income (expense):      
Interest and other income, net 166,113 34,285 147,406
Change in fair value of common stock warrants 1,982,620 8,690,658 2,403,924
Gain (Loss) on investment in affiliated entity 1,631,819 (2,390,498) (969,914)
Net gain (loss) (19,712,980) (15,304,095) (17,638,746)
Net loss attributable to non-controlling interest 44,025 51,150 24,950
Net gain (loss) attributable to Inovio Pharmaceuticals, Inc. $ (19,668,955) $ (15,252,945) $ (17,613,796)
Loss per common share—basic and diluted:      
Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders $ (0.14) $ (0.12) $ (0.17)
Weighted average number of common shares outstanding—basic and diluted 136,509,247 126,239,336 103,201,880